Opus Genetics Wins U.S. Clearance for Gene Therapy Ahead of Phase 1/2 Trial
Key Facts
Opus Genetics announced that its investigational gene therapy for RDH12-related congenital blindness had received clearance from the U.S. Food and Drug Administration, allowing it to advance into clinical development. The company said the agency had cleared its investigational new drug application, a regulatory step that paves the way for testing the treatment in humans. The program targets an inherited disease affecting children, along a development path that still precedes authorization to market the drug. The FDA explains that clinical trials test the safety and efficacy of unapproved drugs before they reach the market. The agency describes these trials as "the ultimate premarket testing ground for unapproved drugs." The program therefore moves into clinical testing under clearance to conduct trials, while the assessment of its safety and efficacy remains part of the development process before marketing.
The treatment candidate works by delivering a functional copy of the target gene to photoreceptors in the retina, according to the company's quarterly report filed with the U.S. Securities and Exchange Commission. The company uses an adeno-associated viral vector to carry the gene into the target cells. Opus said in the filing that preclinical studies had shown "restoration of gene activity and functional improvement." Those findings come from the research stage before testing the treatment in humans, which preceded the current regulatory clearance. In describing the disease, the company said structural changes in the retina could appear by the age of 2 years. The company places this early onset of changes in the medical context of the potential importance of early therapeutic intervention in children with the disease.
Opus Genetics estimates that about 30,900 people worldwide have the disease, according to its disclosure on its gene therapy programs. Of those, the company estimates that 2,500 are in the United States, compared with 17,500 in the Middle East and North Africa. Based on these estimates, the Middle East and North Africa has more people with the disease than the United States and accounts for the largest share of the global total reported by the company. The program is being developed with support from patient foundations under a funding and licensing agreement that took effect on July 22, 2025. The agreement provides up to $1.6 million in funding to support the program's development, according to Opus's quarterly report. That amount is tied to the program covered by the agreement with the funding organizations, while the collaboration also includes arrangements to share development risks.
The company said in its partnership statement that the collaboration with the patient coalition includes "a risk-sharing structure and performance-based milestones." The partnership thus combines funding dedicated to developing the treatment with arrangements linking milestones to performance, according to Opus's description of the agreement. Across the company as a whole, cash and cash equivalents stood at $88.8 million on June 30, 2026. Opus reported that balance in its quarterly report before announcing clearance to move into clinical trials. The cash balance represents its liquidity position at the end of June, while the patient foundations' funding relates to the agreement supporting the program itself. The current regulatory progress comes within development activities funded by the company alongside its collaboration with patient support organizations and the announced partnership arrangements.
In the stock market, the company's shares, traded under the ticker IRD, closed at $4.01 on October 20, 2026, in the session before the clearance announcement. That close preceded the announcement of the regulatory step for the gene therapy, according to the chronology of the news and EL7 data. Also ahead of the announcement, Citizens maintained its outperform rating on the stock. The firm set a price target of $17.00 a share, according to Investing's coverage of its analyst update. This places the analyst assessment and price target in the period before the clearance, alongside the previous session's close at the level cited. The rating in place at the time reflected the firm's stance on Opus shares before the program advanced into clinical development under the U.S. clearance.
As for the next step, Chief Executive George Magrath said the company plans to begin a Phase 1/2 trial this quarter. He added, according to remarks reported by Investing, "We plan to initiate a Phase one/two trial during this quarter." Opus had already projected, in its previous quarterly earnings announcement, that the program would enter clinical development in the fourth quarter of 2026. That timing places the current regulatory clearance within a development schedule the company had announced before receiving it. In its latest presentation, management also said it would prioritize its programs based on scientific evidence and could adjust those priorities if another program showed stronger evidence of benefit. Its stated plan for this treatment remains to launch the trial in the fourth quarter of 2026, following clearance of the investigational new drug application.